Accelerate Diagnostics (AXDX) Misses Q2 EPS by 222c

Accelerate Diagnostics (NASDAQ: AXDX) reported Q2 EPS of ($2.36), $2.22 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.92 million versus the consensus estimate of $3.6 million.

For earnings history and earnings-related data on Accelerate Diagnostics (AXDX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance